Inogen (INGN) Competitors

Inogen (NASDAQ:INGN) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Which has stronger earnings & valuation, INGN or ESTA?

Establishment Labs has lower revenue, but higher earnings than Inogen. Establishment Labs is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$315.66M	0.86	-$102.45M	-$2.25	-5.08
Establishment Labs	$165.15M	5.58	-$78.50M	-$2.58	-12.75

Does the media refer more to INGN or ESTA?

In the previous week, Inogen and Inogen both had 3 articles in the media. Establishment Labs' average media sentiment score of 1.17 beat Inogen's score of 0.96 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer INGN or ESTA?

Inogen received 271 more outperform votes than Establishment Labs when rated by MarketBeat users. Likewise, 69.29% of users gave Inogen an outperform vote while only 61.90% of users gave Establishment Labs an outperform vote.

Company	Underperform	Outperform
Inogen	Outperform Votes 388 69.29%	Underperform Votes 172 30.71%
Establishment Labs	Outperform Votes 117 61.90%	Underperform Votes 72 38.10%

Do analysts rate INGN or ESTA?

Inogen presently has a consensus target price of $7.00, indicating a potential downside of 38.81%. Establishment Labs has a consensus target price of $60.60, indicating a potential upside of 84.25%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts plainly believe Establishment Labs is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Establishment Labs	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of INGN or ESTA?

89.9% of Inogen shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 1.0% of Inogen shares are owned by company insiders. Comparatively, 11.4% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is INGN or ESTA more profitable?

Inogen has a net margin of -15.89% compared to Establishment Labs' net margin of -46.13%. Inogen's return on equity of -27.38% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-15.89%	-27.38%	-16.77%
Establishment Labs	-46.13%	-184.55%	-24.81%

Which has more risk & volatility, INGN or ESTA?

Inogen has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Inogen and Establishment Labs tied by winning 9 of the 18 factors compared between the two stocks.